Company attributes
Other attributes
Hager Biosciences, LLC is a preclinical-stage drug discovery organization based on innovative medicinal chemistry capabilities. Hager's main mission is to become a preferred partner to pharmaceutical and biotech firms by providing therapeutic leads through out-licensing for unmet medical needs. Central to the business model is Hager's capability to design and synthesize proprietary small fragment molecules for modular adaptation into new or existing drug candidate optimization programs. Hager's discovery FragPhoreTM platform provides a competitive advantage for rapid medicinal chemistry optimization and drug rescue via profile/properties improvement, as well as modular fragments for intellectual property enhancement.
The principals and Leadership Team of Hager Biosciences bring to bear over 5 decades of demonstrated accomplishments in pharmaceutical R&D spanning all three critical segments of the pre-clinical drug discovery paradigm:
- Hit to Lead
- Lead Optimization
- Pre-Clinical & Development-track Candidates
Through effective collaboration, fostering and leadership of cross-functional scientists, our leadership team members have contributed significantly to the pipelines of several big pharma and biotech research organizations. These records of accomplishment have been made possible through exacting the practice of modern and classical medicinal chemistry approaches geared towards simultaneous optimization of both biological and physico-chemical properties of drug candidates. Overall, Hager Leadership members have authored/co-authored a combined total of over 65 journal articles and they hold over 65 US or WO patents.
